ATX - Amplia Therapeutics

I'll be checking out the story some more and might buy a small stake as I did with 1AD (Adalta) just to benefit from a possible new spike after I've held for 12 months. Only if impatience for news grinds the price down to the trading range though. I think it spike over 60% yesterday.

Amplia Therapeutics is raising $12.4 million to fund early human clinical trials and drug manufacturing for its oral drug candidate designed to slow the progression of cancers.

The early stage pharmaceutical company has appointed Taylor Collison as the lead manager and the raise will take the form of a placement to institutional investors and an entitlement offer.

Amplia will raise $5.4 million via the placement, while the rest will come from a standard non-renounceable rights issue, will be conducted on a one for four basis.

Participants will also receive an attaching option of one option for every three shares applied for under the placement and entitlement offer.

The offer is priced at 18c per share, representing a 7.7 per cent discount to the last traded price.

Amplia’s AMP945 drug candidate is an oral inhibitor of a Focal Adhesion Kinase (FAK) - a process which promotes tumour progression and metastasis.

Dona Ferentes said:

.. the raise will take the form of a placement to institutional investors and an entitlement offer.
The offer is priced at 18c per share, representing a 7.7 per cent discount

Click to expand...

and this one will be cheaper...
"Trading Halt is requested to allow Amplia to undertake an entitlement offer process."

.... MC of $17mn.

Fully Underwritten 2 for 5 Entitlement Offer to raise $4.27 million
• Amplia is developing a pipeline of small molecule inhibitors of Focal Adhesion Kinase (FAK) - a clinically validated target in cancer
• Amplia’s lead compound narmafotinib (AMP945) is the best-in-class FAK inhibitor in development
• Promising clinical safety and tolerability data positions narmafotinib as the preferred agent to enhance the activity of drugs that are currently standard-of-care, for the treatment of pancreatic cancer and other solid tumours
• The capital raising consists of a two (2) for five (5), fully underwritten pro-rata non-renounceable Entitlement Offer to raise $4.27m
• The New Shares issued under the Entitlement Offer are priced at $0.055 each
• Proceeds from the Entitlement Offer will be used to:
- Provide sufficient funding to undertake the Interim Analysis for the ongoing Phase 2a ACCENT trial
- Undertake production of additional narmafotinib, and manufacture a further batch of 25,000 capsules
- Support a pilot Investigator Initiated Trial in ovarian cancer

HIGHLIGHTS
• Amplia successfully completes its $4.27 million fully underwritten Entitlement Offer.
• The fully underwritten Entitlement Offer announced 16 April 2024 was well supported by existing shareholders and new institutional and sophisticated investors.
• Recruitment in the ongoing Phase 2 ACCENT trial is on track with 19 patients recruited to date.


.
phew.

DNH

Pancreatic cancer is a hard to treat . Phase 2 trial numbers up ...to 26 . Some results next half year.

a number of fund managers on board - Platinum, Acorn, Pengana
MC $25M

up a bit today, now $0.125
.
HIGHLIGHTS
• The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancer
• Fast Track Designation facilitates the development of investigational drugs and allows for expedited review